Helena A Yu

Trials

Studies that name Helena A Yu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 15:12 UTC. Open this list on ClinicalTrials.gov

• Ph3
  NCT04181060 · Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

  National Cancer Institute (NCI) · recruiting · Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma · principal investigator
• Ph2
  NCT03944772 · Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

  AstraZeneca · active not recruiting · Non-Small Cell Lung Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 15:12 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Drivers of histologic transformation in EGFR-mutant lung cancer
  R01CA264078 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2021 to 2025 · $404,888 awarded in 2025
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• ECOG-ACRIN Network Group Operations Center
  U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026
  Named on NCT04181060